<SEC-DOCUMENT>0001356576-25-000031.txt : 20250506
<SEC-HEADER>0001356576-25-000031.hdr.sgml : 20250506
<ACCEPTANCE-DATETIME>20250506161418
ACCESSION NUMBER:		0001356576-25-000031
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		15
CONFORMED PERIOD OF REPORT:	20250506
ITEM INFORMATION:		Results of Operations and Financial Condition
FILED AS OF DATE:		20250506
DATE AS OF CHANGE:		20250506

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			SUPERNUS PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001356576
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				000000000
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35518
		FILM NUMBER:		25917430

	BUSINESS ADDRESS:	
		STREET 1:		9715 KEY WEST AVENUE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		301-838-2500

	MAIL ADDRESS:	
		STREET 1:		9715 KEY WEST AVENUE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	SUPERNUS PHARMACEUTICALS INC
		DATE OF NAME CHANGE:	20060317
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>supn-20250506.htm
<DESCRIPTION>8-K
<TEXT>
<XBRL>
<?xml version='1.0' encoding='ASCII'?>
<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:ff4be088-77b2-4255-8fca-49dc4889cf74,g:77dba2ac-dc7c-4746-b429-683ef8bccfa1,d:66e66ef2f1104d179aa118f998ea745f-->
<html xmlns:xbrli="http://www.xbrl.org/2003/instance" xmlns:ixt-sec="http://www.sec.gov/inlineXBRL/transformation/2015-08-31" xmlns:ix="http://www.xbrl.org/2013/inlineXBRL" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:ixt="http://www.xbrl.org/inlineXBRL/transformation/2020-02-12" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:dei="http://xbrl.sec.gov/dei/2024" xmlns="http://www.w3.org/1999/xhtml" xmlns:link="http://www.xbrl.org/2003/linkbase" xml:lang="en-US"><head><meta http-equiv="Content-Type" content="text/html"/>


<title>supn-20250506</title></head><body><div style="display:none"><ix:header><ix:hidden><ix:nonNumeric contextRef="c-1" name="dei:AmendmentFlag" id="f-21">false</ix:nonNumeric><ix:nonNumeric contextRef="c-1" name="dei:EntityCentralIndexKey" id="f-22">0001356576</ix:nonNumeric></ix:hidden><ix:references xml:lang="en-US"><link:schemaRef xlink:type="simple" xlink:href="supn-20250506.xsd"/></ix:references><ix:resources><xbrli:context id="c-1"><xbrli:entity><xbrli:identifier scheme="http://www.sec.gov/CIK">0001356576</xbrli:identifier></xbrli:entity><xbrli:period><xbrli:startDate>2025-05-06</xbrli:startDate><xbrli:endDate>2025-05-06</xbrli:endDate></xbrli:period></xbrli:context></ix:resources></ix:header></div><div id="i66e66ef2f1104d179aa118f998ea745f_1"></div><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="-sec-extract:summary;text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">UNITED STATES</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">SECURITIES AND EXCHANGE COMMISSION</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Washington, D.C. 20549</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%">FORM&#160;<ix:nonNumeric contextRef="c-1" name="dei:DocumentType" id="f-1">8-K</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">CURRENT REPORT</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Pursuant to Section&#160;13 or 15(d)&#160;of the Securities Exchange Act of 1934</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Date of Report (Date of earliest event reported):</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%"> <ix:nonNumeric contextRef="c-1" name="dei:DocumentPeriodEndDate" format="ixt:date-monthname-day-year-en" id="f-2">May 6, 2025</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:18pt;font-weight:700;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityRegistrantName" id="f-3">Supernus Pharmaceuticals,&#160;Inc.</ix:nonNumeric> </span></div><div style="text-align:center"><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Exact name of registrant as specified in its charter)</span></div><div style="text-align:center"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"/><td style="width:33.987%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:13.812%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:33.989%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityIncorporationStateCountryCode" format="ixt-sec:stateprovnameen" id="f-4">Delaware</ix:nonNumeric></span></div></td><td colspan="6" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityFileNumber" id="f-5">001-35518</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityTaxIdentificationNumber" id="f-6">20-2590184</ix:nonNumeric></span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(State or other jurisdiction of incorporation or organization)</span></div></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Commission File Number)</span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(I.R.S. Employer Identification No.)</span></div></td></tr><tr style="height:3pt"><td colspan="6" style="padding:0 1pt"/><td colspan="6" style="padding:0 1pt"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressAddressLine1" id="f-7">9715 Key West Ave</ix:nonNumeric></span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressCityOrTown" id="f-8">Rockville</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:1.12pt;padding-right:1.12pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressStateOrProvince" id="f-9">MD</ix:nonNumeric></span></div></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:EntityAddressPostalZipCode" id="f-10">20850</ix:nonNumeric></span></div></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Address of Principal Executive Offices)</span></div></td><td colspan="6" style="padding:0 1pt"/><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><div style="margin-bottom:1pt;padding-left:2.25pt;padding-right:2.25pt;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(Zip Code)</span></div></td></tr></table></div><div><span><br/></span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Registrant&#8217;s telephone number, including area code: </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(<ix:nonNumeric contextRef="c-1" name="dei:CityAreaCode" id="f-11">301</ix:nonNumeric>) <ix:nonNumeric contextRef="c-1" name="dei:LocalPhoneNumber" id="f-12">838-2500</ix:nonNumeric> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Not Applicable</span></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(Former name or former address, if changed since last report.)</span></div><div style="text-align:center"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;&#160;Securities registered pursuant to Section 12(b) of the Exchange Act</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:90.789%"><tr><td style="width:1.0%"/><td style="width:39.479%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:16.291%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:40.930%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Title of each class</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Trading Symbol</span></td><td colspan="3" style="border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%;text-decoration:underline">Name of each exchange on which registered</span></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:Security12bTitle" id="f-13">Common Stock, $0.001 par value per share</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:TradingSymbol" id="f-14">SUPN</ix:nonNumeric></span></td><td colspan="3" style="border-bottom:1pt solid #ffffff;border-left:1pt solid #ffffff;border-right:1pt solid #ffffff;border-top:1pt solid #ffffff;padding:2px 1pt;text-align:center;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%"><ix:nonNumeric contextRef="c-1" name="dei:SecurityExchangeName" format="ixt-sec:exchnameen" id="f-15">The Nasdaq Stock Market LLC</ix:nonNumeric></span></td></tr></table></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Check the appropriate box below if the Form&#160;8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline">see</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> General Instruction A.2. below):</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:WrittenCommunications" format="ixt-sec:boolballotbox" id="f-16">&#9744;</ix:nonNumeric></span><span style="color:#ff0000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Written communications pursuant to Rule&#160;425 under the Securities Act (17 CFR 230.425)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:SolicitingMaterial" format="ixt-sec:boolballotbox" id="f-17">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Soliciting material pursuant to Rule&#160;14a-12 under the Exchange Act (17 CFR 240.14a-12)</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementTenderOffer" format="ixt-sec:boolballotbox" id="f-18">&#9744;</ix:nonNumeric> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pre-commencement communications pursuant to Rule&#160;14d-2(b)&#160;under the Exchange Act (17 CFR 240.14d-2(b))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:PreCommencementIssuerTenderOffer" format="ixt-sec:boolballotbox" id="f-19">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Pre-commencement communications pursuant to Rule&#160;13e-4(c)&#160;under the Exchange Act (17 CFR 240.13e-4(c))</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Indicate by check mark whether the registrant is an emerging growth company as defined in Rule&#160;405 of the Securities Act of 1933 (&#167;230.405 of this chapter) or Rule&#160;12b-2 of the Securities Exchange Act of 1934 (&#167;240.12b-2 of this chapter). </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%"><ix:nonNumeric contextRef="c-1" name="dei:EntityEmergingGrowthCompany" format="ixt-sec:boolballotbox" id="f-20">&#9744;</ix:nonNumeric></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section&#160;13(a)&#160;of the Exchange Act. </span><span style="color:#000000;font-family:'Arial Unicode MS',sans-serif;font-size:12pt;font-weight:400;line-height:120%">&#9744;</span><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.853%"><tr><td style="width:1.0%"/><td style="width:98.900%"/><td style="width:0.1%"/></tr><tr style="height:3pt"><td colspan="3" style="border-bottom:3pt double #000000;padding:0 1pt"/></tr></table></div><div style="text-indent:36pt"><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div><span><br/></span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="margin-top:10pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Item 2.02</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:115%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:115%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:115%">Results of Operations and Financial Condition.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">On May 6, 2025, Supernus Pharmaceuticals, Inc. (&#8220;Supernus&#8221; or the &#8220;Company&#8221;) issued a press release regarding its financial results for the first quarter March 31, 2025. A copy of this press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">As previously announced, Supernus is hosting a conference call at 4:30 p.m. Eastern Time on Tuesday, May 6, 2025, to present the business and financial results. A live webcast is available at </span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">www.supernus.com</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The webcast will be archived on the Company&#8217;s website for 60 days following the live call. </span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information in this Item 2.02 (including Exhibit 99.1) is being &#8220;furnished&#8221; and shall not be deemed &#8220;filed&#8221; for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, whether made before or after the date of this report, except as shall be expressly set forth by specific reference in such filing.</span></div><div style="text-indent:36pt"><span><br/></span></div><div style="text-align:justify;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This Current Report on Form 8-K contains &#8220;forward-looking statements&#8221; that do not convey historical information, but relate to predicted or potential future events, such as statements of our plans, strategies and intentions. These statements can often be identified by the use of forward-looking terminology such as &#8220;believe,&#8221; &#8220;expect,&#8221; &#8220;intend,&#8221; &#8220;may,&#8221; &#8220;will,&#8221; &#8220;should,&#8221; or &#8220;anticipate&#8221; or similar terminology. All statements other than statements of historical facts included in this Current Report on Form 8-K are forward-looking statements. All forward-looking statements speak only as of the date of this Current Report on Form 8-K. Except for Supernus&#8217; ongoing obligations to disclose material information under the federal securities laws, Supernus undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise. In addition to the risks and uncertainties of ordinary business operations and conditions in the general economy and the markets in which Supernus competes, the forward-looking statements of Supernus contained in this Current Report on Form 8-K are also subject to various risks and uncertainties, including those set forth in Item 1A, &#8220;Risk Factors,&#8221; in Supernus&#8217; Annual Report on Form 10-K for the fiscal year ended December 31, 2024 which the Company filed on February 25, 2025, and other risk factors set forth from time to time in the Company&#8217;s filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended.</span></div><div style="text-indent:36pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Item 9.01</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Statements and Exhibits*.</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(d)</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:3pt;font-weight:400;line-height:120%">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibits</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="padding-left:36pt;text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit&#160;99.1 &#8212;</span><span style="color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline"><a style="-sec-extract:exhibit;color:#0000ff;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;text-decoration:underline" href="ex991earningsrelease.htm"> Press Release Dated May 6, 2025</a></span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> furnished as an Exhibit pursuant to Item 2.02 hereof.</span></div><div style="text-indent:72pt"><span><br/></span></div><div style="text-indent:72pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Exhibit 104 &#8212; The cover page from this Current Report on Form 8-K, formatted in Inline XBRL.</span></div><div style="text-indent:72pt"><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">______________________________________ </span></div><div><span><br/></span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">* </span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The information furnished under Item 2.02 and Item 9.01 of this Current Report on Form 8-K, including the exhibits, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange act of 1934, as amended, or otherwise subject to liabilities under that section, nor shall it be deemed incorporated by reference in any registration statement or other filings of the Company under the Securities act of 1933, as amended, except as shall be set forth by specific reference in such filing. </span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</span></div></div></div><hr style="page-break-after:always"/><div style="min-height:42.75pt;width:100%"><div><span><br/></span></div></div><div style="text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">SIGNATURES</span></div><div><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</span></div><div style="text-indent:36pt"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.&#160;</span></div><div style="text-indent:36pt"><span><br/></span></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:98.099%"><tr><td style="width:1.0%"/><td style="width:50.017%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:3.221%"/><td style="width:0.1%"/><td style="width:1.0%"/><td style="width:43.462%"/><td style="width:0.1%"/></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">SUPERNUS PHARMACEUTICALS,&#160;INC.</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="6" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#160;</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:bottom"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">DATED: May 6, 2025</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">By:</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">/s/ Timothy Dec</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Timothy Dec</span></td></tr><tr><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:1pt;font-weight:400;line-height:100%">&#160;</span></td><td colspan="3" style="padding:2px 1pt;text-align:left;vertical-align:top"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Senior Vice-President and Chief Financial Officer</span></td></tr></table></div><div><span><br/></span></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="-sec-extract:summary;text-align:center"><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</span></div></div></div></body></html>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex991earningsrelease.htm
<DESCRIPTION>EX-99.1
<TEXT>
<html><head>
<!-- Document created using Wdesk -->
<!-- Copyright 2025 Workiva -->
<title>Document</title></head><body><div id="i06c466b0cc99412d804d95e2da3d5b25_1"></div><div style="min-height:42.75pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:right"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Exhibit 99.1</font></div><div><img alt="supernuslogoa.jpg" src="supernuslogoa.jpg" style="height:71px;margin-bottom:5pt;vertical-align:text-bottom;width:306px"></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#160;</font></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:12pt;font-weight:700;line-height:120%">Supernus Announces First Quarter 2025 Financial Results</font></div><div><font><br></font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">First quarter 2025 net sales of Qelbree</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased 44% to $64.7 million, compared to the same period in 2024. </font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">First quarter 2025 net sales of GOCOVRI</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased 16% to $30.7 million, compared to the same period in 2024. </font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">First quarter 2025 total revenues increased 4% to $149.8 million, compared to the same period in 2024. First quarter 2025 total revenues excluding Trokendi XR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Oxtellar XR</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> net sales (non-GAAP)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> increased 26% compared to the first quarter of 2024.</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">First quarter 2025 operating loss of $(10.3) million, compared to operating loss of $(3.2) million in 2024. First quarter adjusted operating earnings (non-GAAP)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">increased 16% to $25.9 million. </font></div><div><font><br></font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">ONAPGO&#8482; (apomorphine hydrochloride) launched in the U.S. in April 2025.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company reiterates full year 2025 financial guidance. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">ROCKVILLE, MD, May 6, 2025 </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8211; </font><font style="background-color:#ffffff;color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supernus Pharmaceuticals, Inc. (Nasdaq&#58; SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced financial results for the first quarter 2025 and associated Company developments.</font></div><div style="text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8220;Our first quarter results reflect, once again, double-digit revenue growth from our core products, as well as strong growth in adjusted operating earnings,&#8221; said Jack Khattar, President and CEO of Supernus. &#8220;In addition, we are pleased to be bringing ONAPGO to market, another growth driver for our business. ONAPGO represents a novel approach for adults with Parkinson&#8217;s disease who are experiencing motor fluctuations.&#8221;</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Commercial Highlights</font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Total IQVIA prescriptions</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> for Qelbree were 214,908 for the first quarter 2025, an increase of 22% compared to the same period in the prior year. For March 2025, total monthly prescriptions reached an all-time high of 75,277. Qelbree continues to expand its base of prescribers, with approximately 34,416 prescribers in the first quarter of 2025, up from 27,902 prescribers in the same period last year. </font></div><div style="text-align:justify"><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">In April 2025, the Company launched ONAPGO, the first and only subcutaneous apomorphine infusion device for the treatment of motor fluctuations in adults with advanced Parkinson&#8217;s disease. Initial physician response is encouraging based on very early activity in the launch.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Product Pipeline Update</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPN-817 &#8211; Novel first-in-class highly selective AChE inhibitor for epilepsy </font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Phase 2b randomized, double-blind, placebo-controlled study of 3mg and 4mg twice daily doses is ongoing with a targeted enrollment of approximately 258 adult patients with treatment resistant focal seizures.</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPN-820 &#8211; Novel first-in-class molecule that increases mTORC1 mediated synaptic function for depression </font></div><div><font><br></font></div><div style="padding-left:36pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">The Company plans to initiate a follow-on Phase 2b multi-center, randomized, double-blind, placebo-controlled trial in approximately 200 adults with major depressive disorder (MDD). The study will examine the safety and tolerability of SPN-820 2400 mg given intermittently (twice weekly) as an adjunctive treatment to the current baseline antidepressant therapy, as well as assess the rapid onset of improvement in depressive symptoms.  </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">1</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">SPN-443 &#8211; Novel stimulant for ADHD&#47;CNS</font></div><div style="padding-left:36pt;text-indent:-18pt"><font style="color:#000000;font-family:'Aptos',san-serif;font-size:12pt;font-weight:400;line-height:112%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:112%;padding-left:12.37pt">The Company completed a Phase 1 pharmacokinetic study of two oral formulations in healthy adults. Both formulations of SPN-443 showed adequate bioavailability and were well tolerated. The Company expects to disclose a lead indication for the product candidate by the end of 2025.</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Financial Highlights</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This section includes information on non-GAAP financial measures. See &#8220;Non-GAAP Financial Information&#8221; section for information on non-GAAP financial measures. In addition, a reconciliation of applicable GAAP to non-GAAP financial information is included at the end of this press release.</font></div><div style="margin-bottom:10pt;margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Revenues</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">The following table provides information regarding total revenues (dollars in millions)&#58;</font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td><td colspan="6" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="border-bottom:1pt solid #000000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change %</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Qelbree</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">64.7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">45.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">44%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">GOCOVRI</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30.7&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.5&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">APOKYN</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15.0&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trokendi XR</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">12.8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16.0&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oxtellar XR</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">10.2&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26.9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.6&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total net product sales</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142.0&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138.4&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty, licensing and other revenues</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(4)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.2&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">51%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.8&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.6&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues excluding Trokendi XR and Oxtellar XR net sales (non-GAAP)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.8&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.7&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Other Financial Highlights</font></div><div style="padding-left:18pt;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Operating loss was $(10.3) million for the three months ended March&#160;31, 2025, compared to operating loss of $(3.2) million for the same period in 2024. The change was primarily due to higher contingent consideration loss, mainly related to the achievement of ONAPGO-related milestones, and higher selling and marketing expenses. </font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Adjusted operating earnings (non-GAAP) were $25.9 million for the three months ended March&#160;31, 2025, compared to $22.3 million for the same period in 2024. </font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">Net loss and diluted loss per share were $(11.8) million and $(0.21) for the three months ended March&#160;31, 2025, compared to net earnings and diluted earnings per share of $0.1 million and $0.00 for the three months ended March&#160;31, 2024.</font></div><div style="margin-bottom:10pt;margin-top:10pt;padding-left:18pt;text-align:justify;text-indent:-18pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">&#8226;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%;padding-left:14.5pt">At March&#160;31, 2025, cash, cash equivalents, and current and long-term marketable securities were approximately $463.6 million compared to $453.6 million as of December&#160;31, 2024. This increase was primarily due to cash generated from operations partially offset by the $25.0 million payment of ONAPGO-related milestone in the first quarter of 2025. </font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">2</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Full Year 2025 Financial Guidance</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For the full year 2025, the Company reiterates its full year financial guidance as set forth below (dollars in millions)&#58;</font></div><div><font><br></font></div><div><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:52.701%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:45.099%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Guidance<br>(as of February 25, 2025)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues (</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:100%">includes approximately $65 million - $75 million of Trokendi XR and Oxtellar XR)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(5)(6)</font></div></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$600 - $630</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Combined R&#38;D and SG&#38;A expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$435 - $460</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating earnings (loss)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$(15) - $10</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjusted operating earnings (non-GAAP)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$105 - $130</font></td></tr></table></div><div style="margin-top:10pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Non-GAAP Financial Information</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This press release contains financial measures that present financial information which do not comply with United States generally accepted accounting principles (GAAP). The non-GAAP financial measures should be considered in addition to, not as a substitute for or in isolation from, or superior to measures prepared in accordance with GAAP. Non-GAAP adjusted operating earnings on a historical and projected basis adjusts for non-cash share-based compensation expense, depreciation and amortization, intangible asset impairment charges and changes to fair value of contingent consideration, and for factors that are unusual, non-recurring or unpredictable, and excludes those costs, expenses, and other specified items presented in the reconciliation tables in this press release. In addition to non-GAAP adjusted operating earnings, we also present total revenues excluding net sales of Trokendi XR (GAAP) and Oxtellar XR (GAAP), which is a non-GAAP measure and is calculated as total revenues (GAAP) less net product sales of Trokendi XR (GAAP) and Oxtellar XR (GAAP). Beginning in the year a product loses exclusivity due to generic entrants, we generally do not expect net product sales of such products to constitute a significant part of our revenue in the future. We believe that the use of non-GAAP financial measures provides useful supplemental information to management, investors, analysts and others regarding the Company&#8217;s revenue and results of operations and assist management, investors, analysts, and others in understanding and evaluating our revenue growth and the performance of the business. </font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">There are limitations associated with the use of non-GAAP financial measures and therefore comparability may be limited. These limitations include&#58; non-GAAP financial measures that may not be entirely comparable to similarly titled measures used by other companies&#59; these may not reflect all items of income and expense, as applicable, that affect our operations&#59; there may be potential differences among calculation methodologies&#59; these may differ from the non-GAAP information used by other companies, including peer companies. We mitigate these limitations by reconciling the non-GAAP financial measure to the most comparable GAAP financial measure. Investors are encouraged to review the reconciliation. The Company&#8217;s 2025 financial guidance is also being provided on both a GAAP and a non-GAAP basis.</font></div><div style="margin-top:1pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:99.415%"><tr><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:18.900%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="border-bottom:1pt solid #000;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">End Notes</font></td><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> See the section titled &#8220;Non-GAAP Financial Information&#8221; for information about this non-GAAP financial measure. A reconciliation of each non-GAAP financial measure to the most directly comparable GAAP financial measure is included at the end of this press release.</font></div><div style="margin-top:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(2)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> IQVIA data restatement July 1, 2024.</font></div><div style="margin-top:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(3)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes net product sales of MYOBLOC</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">, XADAGO</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> and Osmolex ER</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">&#174;</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(4) </font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Royalty, licensing, and other revenues include royalties on generic Trokendi XR, Oxtellar XR, other licensed products and intellectual property.</font></div><div style="margin-top:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(5)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes net product sales and royalty, licensing, and other revenue.</font></div><div style="margin-top:1pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(6)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Reflects continued generic erosion of Trokendi XR and generic erosion of Oxtellar XR beginning in September 2024. </font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Conference Call Details</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supernus will host a conference call and webcast today, May 6, 2025, at 4&#58;30 p.m. Eastern Time to discuss these results.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">A live webcast will be available in the </font><font style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Events &#38; Presentations</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> section of the Company&#8217;s Investor Relations website </font><font style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">www.supernus.com&#47;investors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-bottom:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Participants may also pre-register any time before the call </font><font style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">here</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. Once registration is completed, participants will be provided a dial-in number with a personalized conference code to access the call. Please dial in 15 minutes prior to the start time.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">3</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Following the live call, a replay will be available on the Company's Investor Relations website </font><font style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">www.supernus.com&#47;investors</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">. The webcast will be available on the Company&#8217;s website for 60 days following the live call.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">About Supernus Pharmaceuticals, Inc.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supernus Pharmaceuticals is a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Our diverse neuroscience portfolio includes approved treatments for attention-deficit hyperactivity disorder (ADHD), dyskinesia in Parkinson&#8217;s disease (PD) patients receiving levodopa-based therapy, hypomobility in PD, epilepsy, migraine, cervical dystonia, and chronic sialorrhea. We are developing a broad range of novel CNS product candidates including new potential treatments for epilepsy, depression, and other CNS disorders.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">For more information, please visit </font><font style="color:#0e32e1;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">www.supernus.com</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">.</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Forward-Looking Statements</font></div><div style="text-align:justify"><font><br></font></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">This press release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These statements do not convey historical information but relate to predicted or potential future events that are based upon management's current expectations. These statements are subject to risks and uncertainties that could cause actual results to differ materially from those expressed or implied by such statements. In addition to the factors mentioned in this press release, such risks and uncertainties include, but are not limited to, the Company&#8217;s ability to sustain and increase its profitability&#59; the Company&#8217;s ability to raise sufficient capital to fully implement its corporate strategy&#59; the implementation of the Company&#8217;s corporate strategy&#59; the Company&#8217;s future financial performance and projected expenditures&#59; the Company&#8217;s ability to increase the number of prescriptions written for each of its products and the products of its subsidiaries&#59; the Company&#8217;s ability to increase its net revenue from its products and the products of its subsidiaries&#59; the Company&#8217;s ability to commercialize its products and the products of its subsidiaries&#59; the Company&#8217;s ability to enter into future collaborations with pharmaceutical companies and academic institutions or to obtain funding from government agencies&#59; the Company&#8217;s product research and development activities, including the timing and progress of the Company&#8217;s clinical trials, and projected expenditures&#59; the Company&#8217;s ability to receive, and the timing of any receipt of, regulatory approvals to develop and commercialize the Company&#8217;s product candidates&#59; the Company&#8217;s ability to protect its intellectual property and the intellectual property of its subsidiaries and operate its business without infringing upon the intellectual property rights of others&#59; the Company&#8217;s expectations regarding federal, state and foreign regulatory requirements&#59; the therapeutic benefits, effectiveness and safety of the Company&#8217;s product candidates&#59; the accuracy of the Company&#8217;s estimates of the size and characteristics of the markets that may be addressed by its product candidates&#59; the Company&#8217;s ability to increase its manufacturing capabilities for its products and product candidates&#59; the Company&#8217;s projected markets and growth in markets&#59; the Company&#8217;s product formulations and patient needs and potential funding sources&#59; the Company&#8217;s staffing needs&#59; changes to laws and regulations applicable to our industry, the impact of macroeconomic factors, such as economic downturns or uncertainty, international conflict, trade disputes and tariffs&#59; and other risk factors set forth from time to time in the Company&#8217;s filings with the Securities and Exchange Commission made pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934, as amended. The Company undertakes no obligation to update the information in this press release to reflect events or circumstances after the date hereof or to reflect the occurrence of anticipated or unanticipated events.</font></div><div style="margin-top:10pt;text-align:justify"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">4</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:10pt;text-align:center;text-indent:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supernus Pharmaceuticals,&#160;Inc.</font></div><div style="text-align:center;text-indent:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Balance Sheets</font></div><div style="text-align:center;text-indent:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</font></div><div style="text-align:center;text-indent:2.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:75.336%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.394%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.374%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.396%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">March 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">December 31,</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Assets</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current assets</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cash and cash equivalents</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">115,848&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">69,331&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Marketable securities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">347,742&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">384,281&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts receivable, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">145,640&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">142,077&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Inventories, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">49,423&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,293&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Prepaid expenses and other current assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">28,931&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">36,088&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current assets</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">687,584&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">686,070&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Property and equipment, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,338&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">11,545&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Intangible assets, net</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">502,126&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">521,912&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Goodwill</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,019&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">117,019&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">29,223&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">31,527&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total assets</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347,290&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368,073&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Liabilities and stockholders&#8217; equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Current liabilities</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accounts payable and accrued liabilities</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,891&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">76,352&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accrued product returns and rebates</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">170,133&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">168,705&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration, current portion</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">30,000&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">47,340&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other current liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,748&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total current liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">281,772&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">292,397&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Operating lease liabilities, long-term</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,368&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">27,382&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Deferred income tax liabilities, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">981&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,961&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 12.25pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Other liabilities</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,464&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,600&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities</font></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">316,585&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">332,340&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Commitments and contingencies</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr style="height:14pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Stockholders&#8217; equity</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:12pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Common stock, $0.001 par value&#59; 130,000,000 shares authorized&#59; 55,989,248 and 55,743,095 shares issued and outstanding as of March 31, 2025 and December&#160;31, 2024, respectively</font></div></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">56&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Additional paid-in capital</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">486,209&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">479,440&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Accumulated other comprehensive loss, net of tax</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(159)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(189)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Retained earnings</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">544,599&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">556,426&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total stockholders&#8217; equity</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,030,705&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,035,733&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total liabilities and stockholders&#8217; equity</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,347,290&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">1,368,073&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000000;border-top:1pt solid #000000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-top:10pt"><font><br></font></div><div style="margin-top:10pt;text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">5</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-top:10pt;text-align:center;text-indent:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supernus Pharmaceuticals,&#160;Inc.</font></div><div style="text-align:center;text-indent:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Consolidated Statements of Earnings (Loss)</font></div><div style="text-align:center;text-indent:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(in thousands, except share and per share data)</font></div><div style="text-align:center;text-indent:2.25pt"><font><br></font></div><div style="text-align:center;text-indent:2.25pt"><font><br></font></div><div style="padding-left:18pt;padding-right:18pt;text-align:center;text-indent:2.25pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:87.865%"><tr><td style="width:1.0%"></td><td style="width:72.776%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:12.211%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.465%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:11.048%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="background-color:#ffffff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-bottom:1pt solid #000;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">(unaudited)</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Revenues</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Net product sales</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">141,988&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">138,461&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Royalty, licensing and other revenues</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,836&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,183&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total revenues</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149,824&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143,644&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt 0 7.75pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Costs and expenses</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div style="padding-left:6pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Cost of goods sold</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font></div></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">15,763&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">16,309&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Research and development</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26,927&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">24,930&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Selling, general and administrative</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">89,944&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">86,516&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19,786&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20,137&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration loss (gain)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7,660&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1,095)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total costs and expenses</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">160,080&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">146,797&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating loss</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10,256)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3,153)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Other income (expense)</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 13pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Interest and other income, net</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,425&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,396&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Total other income (expense), net</font></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4,425&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">3,396&#160;</font></td><td style="background-color:#ffffff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings (loss) before income taxes</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(5,831)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">243&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Income tax expense</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5,996&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">119&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Net earnings (loss)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(11,827)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">124&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;border-top:3pt double #000;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Earnings (Loss) per share</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#ffffff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(0.21)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">&#8212;&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr style="height:15pt"><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Weighted average shares outstanding</font></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Basic</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,864,692&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">54,801,748&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:top"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Diluted</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,864,692&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">55,626,663&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="padding-left:36pt;text-indent:-31.5pt"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:68.274%"><tr><td style="width:1.0%"></td><td style="width:35.516%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:43.653%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:5.966%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:3.399%"></td><td style="width:0.1%"></td></tr><tr style="height:6pt"><td colspan="3" style="border-bottom:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td></tr></table></div><div style="padding-left:9pt;text-indent:-4.5pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(a)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Excludes amortization of intangible assets.</font></div><div style="margin-top:10pt;text-align:center"><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">6</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Supernus Pharmaceuticals, Inc.</font></div><div style="text-align:center;text-indent:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Reconciliations of GAAP to Non-GAAP Financial Information</font></div><div style="text-align:center;text-indent:2.25pt"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">(unaudited)</font></div><div style="text-align:center"><font><br></font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reconciliation of GAAP Total revenues to Non-GAAP Total revenues excluding Trokendi XR and Oxtellar XR net sales</font></div><div style="margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An itemized reconciliation between total revenues on a GAAP basis and Total revenues excluding Trokendi XR and Oxtellar XR net sales, a non-GAAP measure, is as follows (dollars in millions)&#58;</font></div><div style="text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:62.642%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.600%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended March 31,</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Change %</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues (GAAP)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">149.8&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">143.6&#160;</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">4%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Trokendi XR net product sales</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(12.8)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(16.0)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(20)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 7pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Oxtellar XR net product sales</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.2)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(26.9)</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(62)%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:top"><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Total revenues excluding Trokendi XR and Oxtellar XR net sales (non-GAAP)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:100%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font></div></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">126.8&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">100.7&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">26%</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">___________________________________________</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:6.5pt;font-weight:400;line-height:120%;position:relative;top:-3.5pt;vertical-align:baseline">(1)</font><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> Includes net product sales and royalty, licensing, and other revenues.</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reconciliation of GAAP Operating Loss to Non-GAAP Adjusted Operating Earnings</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An itemized reconciliation between operating loss on a GAAP basis and adjusted operating earnings on a non-GAAP basis is as follows (dollars in millions)&#58;</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:74.923%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.595%"></td><td style="width:0.1%"></td><td style="width:0.1%"></td><td style="width:0.384%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:10.598%"></td><td style="width:0.1%"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="9" style="padding:2px 1pt;text-align:center;vertical-align:middle"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Three Months Ended<br>March 31,</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2025</font></td><td colspan="3" style="border-top:1pt solid #000;padding:0 1pt"></td><td colspan="3" style="border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">2024</font></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating loss - As Reported (GAAP)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(10.3)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(3.2)</font></td><td style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">19.8&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">20.1&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">8.1&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">5.9&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration loss (gain)</font></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">7.7&#160;</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td colspan="2" style="background-color:#cceeff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">(1.1)</font></td><td style="background-color:#cceeff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 10pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation </font></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td><td colspan="2" style="background-color:#ffffff;padding:2px 0 2px 1pt;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">0.6&#160;</font></td><td style="background-color:#ffffff;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating earnings - As Adjusted (non-GAAP)</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">25.9&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="background-color:#cceeff;padding:0 1pt"></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0 2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 0;text-align:right;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">22.3&#160;</font></td><td style="background-color:#cceeff;border-bottom:3pt double #000;border-top:1pt solid #000;padding:2px 1pt 2px 0;text-align:right;vertical-align:bottom"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td><td colspan="3" style="display:none"></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Non-GAAP adjusted operating earnings adjusts for non-cash items including amortization of intangible assets, share-based compensation expense, change in fair value of contingent consideration, intangible assets impairment charges, and depreciation.</font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">7</font></div></div></div><hr style="page-break-after:always"><div style="min-height:42.75pt;width:100%"><div><font><br></font></div><div><font><br></font></div></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:400;line-height:120%">Reconciliation of Full Year 2025 Financial Guidance - GAAP Operating Earnings (Loss) to Non-GAAP Adjusted Operating Earnings</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">An itemized reconciliation between projected operating earnings (loss) on a GAAP basis for the full year 2025 and projected adjusted operating earnings on a non-GAAP basis for the full year 2025 is as follows (dollars in millions)&#58;</font></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><table style="border-collapse:collapse;display:inline-table;margin-bottom:5pt;vertical-align:text-bottom;width:100.000%"><tr><td style="width:1.0%"></td><td style="width:56.940%"></td><td style="width:0.1%"></td><td style="width:1.0%"></td><td style="width:40.860%"></td><td style="width:0.1%"></td></tr><tr><td colspan="3" style="padding:0 1pt"></td><td colspan="3" style="padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Current Guidance<br>(as of February 25, 2025)</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating earnings (loss) - GAAP</font></td><td colspan="3" style="background-color:#cceeff;border-top:1pt solid #000;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$(15) - $10</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Adjustments&#58;</font></td><td colspan="3" style="background-color:#ffffff;padding:0 1pt"></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Amortization of intangible assets</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$81 - $84</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Share-based compensation</font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$30 - $34</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Contingent consideration loss</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$7 - $8</font></td></tr><tr><td colspan="3" style="background-color:#ffffff;padding:2px 1pt 2px 4pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">Depreciation </font></td><td colspan="3" style="background-color:#ffffff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$2 - $3</font></td></tr><tr><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:left;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:100%">Operating earnings - As Adjusted (non-GAAP)</font></td><td colspan="3" style="background-color:#cceeff;padding:2px 1pt;text-align:center;vertical-align:bottom"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:100%">$105 - $130</font></td></tr></table></div><div style="margin-bottom:10pt;margin-top:10pt;text-align:justify"><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">CONTACTS&#58;</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Jack A. Khattar, President and CEO</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Timothy C. Dec, Senior Vice President and CFO</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Supernus Pharmaceuticals, Inc.</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(301) 838-2591</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">or</font></div><div><font><br></font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">INVESTOR CONTACT&#58;</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">Peter Vozzo</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">ICR Healthcare</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">(443) 213-0505</font></div><div><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">peter.vozzo&#64;icrhealthcare.com</font></div><div><font><br></font></div><div style="height:42.75pt;position:relative;width:100%"><div style="bottom:0;position:absolute;width:100%"><div style="text-align:center"><font style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%">8</font></div></div></div></body></html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.SCH
<SEQUENCE>3
<FILENAME>supn-20250506.xsd
<DESCRIPTION>XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:ff4be088-77b2-4255-8fca-49dc4889cf74,g:77dba2ac-dc7c-4746-b429-683ef8bccfa1-->
<xs:schema xmlns:xs="http://www.w3.org/2001/XMLSchema" xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:supn="http://www.supernus.com/20250506" attributeFormDefault="unqualified" elementFormDefault="qualified" targetNamespace="http://www.supernus.com/20250506">
  <xs:import namespace="http://www.xbrl.org/2003/instance" schemaLocation="http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd"/>
  <xs:import namespace="http://www.xbrl.org/2003/linkbase" schemaLocation="http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd"/>
  <xs:import namespace="http://xbrl.sec.gov/dei/2024" schemaLocation="https://xbrl.sec.gov/dei/2024/dei-2024.xsd"/>
  <xs:annotation>
    <xs:appinfo>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="supn-20250506_pre.xml" xlink:role="http://www.xbrl.org/2003/role/presentationLinkbaseRef" xlink:type="simple"/>
      <link:linkbaseRef xmlns:xlink="http://www.w3.org/1999/xlink" xlink:arcrole="http://www.w3.org/1999/xlink/properties/linkbase" xlink:href="supn-20250506_lab.xml" xlink:role="http://www.xbrl.org/2003/role/labelLinkbaseRef" xlink:type="simple"/>
      <link:roleType id="CoverPage" roleURI="http://www.supernus.com/role/CoverPage">
        <link:definition>0000001 - Document - Cover Page</link:definition>
        <link:usedOn>link:presentationLink</link:usedOn>
        <link:usedOn>link:calculationLink</link:usedOn>
        <link:usedOn>link:definitionLink</link:usedOn>
      </link:roleType>
    </xs:appinfo>
  </xs:annotation>
</xs:schema>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.LAB
<SEQUENCE>4
<FILENAME>supn-20250506_lab.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:ff4be088-77b2-4255-8fca-49dc4889cf74,g:77dba2ac-dc7c-4746-b429-683ef8bccfa1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodStartLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodStartLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/netLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/net-2009-12-16.xsd#netLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedNetLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedNetLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTerseLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTerseLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedPeriodEndLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedPeriodEndLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedLabel"/>
  <link:roleRef roleURI="http://www.xbrl.org/2009/role/negatedTotalLabel" xlink:type="simple" xlink:href="http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd#negatedTotalLabel"/>
  <link:labelLink xlink:role="http://www.xbrl.org/2003/role/link" xlink:type="extended">
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_3f9b7b6d-5081-438c-a234-20245d6cf183_terseLabel_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:label id="lab_dei_EntityIncorporationStateCountryCode_label_en-US" xlink:label="lab_dei_EntityIncorporationStateCountryCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Incorporation, State or Country Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityIncorporationStateCountryCode" xlink:to="lab_dei_EntityIncorporationStateCountryCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityCentralIndexKey_5747c52f-558a-4d3b-9103-7dac6e7e7813_terseLabel_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:label id="lab_dei_EntityCentralIndexKey_label_en-US" xlink:label="lab_dei_EntityCentralIndexKey" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Central Index Key</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityCentralIndexKey" xlink:to="lab_dei_EntityCentralIndexKey" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityFileNumber_93551eb5-7dd7-4b78-a3b0-7c000834714e_terseLabel_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Filer Name</link:label>
    <link:label id="lab_dei_EntityFileNumber_label_en-US" xlink:label="lab_dei_EntityFileNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity File Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityFileNumber" xlink:to="lab_dei_EntityFileNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressStateOrProvince_6d8c9396-23d5-43c7-9afc-a43203dce5b1_terseLabel_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:label id="lab_dei_EntityAddressStateOrProvince_label_en-US" xlink:label="lab_dei_EntityAddressStateOrProvince" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, State or Province</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressStateOrProvince" xlink:to="lab_dei_EntityAddressStateOrProvince" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SecurityExchangeName_3ea13d37-4e31-484f-ba39-c1a4705e03e5_terseLabel_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:label id="lab_dei_SecurityExchangeName_label_en-US" xlink:label="lab_dei_SecurityExchangeName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Security Exchange Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SecurityExchangeName" xlink:to="lab_dei_SecurityExchangeName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_4adac951-a589-4c81-aa08-0b9bb140ab18_terseLabel_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementIssuerTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementIssuerTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Issuer Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementIssuerTenderOffer" xlink:to="lab_dei_PreCommencementIssuerTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressAddressLine1_f6485f72-6041-4c97-8845-ad3ba2527bbe_terseLabel_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:label id="lab_dei_EntityAddressAddressLine1_label_en-US" xlink:label="lab_dei_EntityAddressAddressLine1" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Address Line One</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressAddressLine1" xlink:to="lab_dei_EntityAddressAddressLine1" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressCityOrTown_9e2fd03b-666f-49da-a033-a54a1e7bf058_terseLabel_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:label id="lab_dei_EntityAddressCityOrTown_label_en-US" xlink:label="lab_dei_EntityAddressCityOrTown" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, City or Town</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressCityOrTown" xlink:to="lab_dei_EntityAddressCityOrTown" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_SolicitingMaterial_8db0fee9-223a-4387-8b6f-fad003432286_terseLabel_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:label id="lab_dei_SolicitingMaterial_label_en-US" xlink:label="lab_dei_SolicitingMaterial" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Soliciting Material</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_SolicitingMaterial" xlink:to="lab_dei_SolicitingMaterial" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityAddressPostalZipCode_87ed7f69-f917-47ee-8a46-c197969bd950_terseLabel_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:label id="lab_dei_EntityAddressPostalZipCode_label_en-US" xlink:label="lab_dei_EntityAddressPostalZipCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Address, Postal Zip Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityAddressPostalZipCode" xlink:to="lab_dei_EntityAddressPostalZipCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CoverAbstract_7f35702c-ea8b-499b-a518-996fdbb461c6_terseLabel_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:label id="lab_dei_CoverAbstract_label_en-US" xlink:label="lab_dei_CoverAbstract" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Cover [Abstract]</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CoverAbstract" xlink:to="lab_dei_CoverAbstract" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_WrittenCommunications_3f4160bd-9de3-496d-81a3-5fd7cc3446b1_terseLabel_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:label id="lab_dei_WrittenCommunications_label_en-US" xlink:label="lab_dei_WrittenCommunications" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Written Communications</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_WrittenCommunications" xlink:to="lab_dei_WrittenCommunications" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_LocalPhoneNumber_9f788591-7891-4899-a1e9-30f6661538ce_terseLabel_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:label id="lab_dei_LocalPhoneNumber_label_en-US" xlink:label="lab_dei_LocalPhoneNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Local Phone Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_LocalPhoneNumber" xlink:to="lab_dei_LocalPhoneNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_Security12bTitle_f28e87ad-080e-47cf-a35a-2c28e9182783_terseLabel_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:label id="lab_dei_Security12bTitle_label_en-US" xlink:label="lab_dei_Security12bTitle" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Title of 12(b) Security</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_Security12bTitle" xlink:to="lab_dei_Security12bTitle" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_CityAreaCode_8e2ccc88-6e0a-413f-b7ff-3f3b91906b85_terseLabel_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:label id="lab_dei_CityAreaCode_label_en-US" xlink:label="lab_dei_CityAreaCode" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">City Area Code</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_CityAreaCode" xlink:to="lab_dei_CityAreaCode" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentPeriodEndDate_ae58ed79-d378-4c18-a3df-3b7de137b01e_terseLabel_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:label id="lab_dei_DocumentPeriodEndDate_label_en-US" xlink:label="lab_dei_DocumentPeriodEndDate" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Period End Date</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentPeriodEndDate" xlink:to="lab_dei_DocumentPeriodEndDate" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_AmendmentFlag_f8752fac-422b-4d7d-959f-33292f322839_terseLabel_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:label id="lab_dei_AmendmentFlag_label_en-US" xlink:label="lab_dei_AmendmentFlag" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Amendment Flag</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_AmendmentFlag" xlink:to="lab_dei_AmendmentFlag" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_dfb67d17-0c6a-41d6-9403-5e807a4e669a_terseLabel_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:label id="lab_dei_EntityTaxIdentificationNumber_label_en-US" xlink:label="lab_dei_EntityTaxIdentificationNumber" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Tax Identification Number</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityTaxIdentificationNumber" xlink:to="lab_dei_EntityTaxIdentificationNumber" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_TradingSymbol_9174ab2e-1bec-4682-bc65-3d4eba42606f_terseLabel_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:label id="lab_dei_TradingSymbol_label_en-US" xlink:label="lab_dei_TradingSymbol" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Trading Symbol</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_TradingSymbol" xlink:to="lab_dei_TradingSymbol" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityRegistrantName_64d7a68a-bb41-4eb4-98e0-d164be5fb3af_terseLabel_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:label id="lab_dei_EntityRegistrantName_label_en-US" xlink:label="lab_dei_EntityRegistrantName" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Registrant Name</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityRegistrantName" xlink:to="lab_dei_EntityRegistrantName" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_PreCommencementTenderOffer_1b8ef069-4da4-496b-bdad-c2deb6e1839e_terseLabel_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:label id="lab_dei_PreCommencementTenderOffer_label_en-US" xlink:label="lab_dei_PreCommencementTenderOffer" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Pre-commencement Tender Offer</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_PreCommencementTenderOffer" xlink:to="lab_dei_PreCommencementTenderOffer" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_DocumentType_3673078a-4574-49d1-9883-1ab723fda90b_terseLabel_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:label id="lab_dei_DocumentType_label_en-US" xlink:label="lab_dei_DocumentType" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Document Type</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_DocumentType" xlink:to="lab_dei_DocumentType" xlink:type="arc" order="1"/>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_4e903eab-3cc9-41f6-8db0-8ff34af29246_terseLabel_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/terseLabel" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:label id="lab_dei_EntityEmergingGrowthCompany_label_en-US" xlink:label="lab_dei_EntityEmergingGrowthCompany" xlink:role="http://www.xbrl.org/2003/role/label" xlink:type="resource" xml:lang="en-US">Entity Emerging Growth Company</link:label>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:labelArc xlink:arcrole="http://www.xbrl.org/2003/arcrole/concept-label" xlink:from="loc_dei_EntityEmergingGrowthCompany" xlink:to="lab_dei_EntityEmergingGrowthCompany" xlink:type="arc" order="1"/>
  </link:labelLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-101.PRE
<SEQUENCE>5
<FILENAME>supn-20250506_pre.xml
<DESCRIPTION>XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT
<TEXT>
<XBRL>
<?xml version="1.0" encoding="UTF-8"?>

<!--XBRL Document Created with the Workiva Platform-->
<!--Copyright 2025 Workiva-->
<!--r:ff4be088-77b2-4255-8fca-49dc4889cf74,g:77dba2ac-dc7c-4746-b429-683ef8bccfa1-->
<link:linkbase xmlns:link="http://www.xbrl.org/2003/linkbase" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.xbrl.org/2003/linkbase http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd">
  <link:roleRef roleURI="http://www.supernus.com/role/CoverPage" xlink:type="simple" xlink:href="supn-20250506.xsd#CoverPage"/>
  <link:presentationLink xlink:role="http://www.supernus.com/role/CoverPage" xlink:type="extended">
    <link:loc xlink:type="locator" xlink:label="loc_dei_CoverAbstract_9a4e73cf-aca7-42d8-b07c-6bd46f859c58" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CoverAbstract"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentType_09b42bc4-586f-47b7-8d28-6fdd7e24a163" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentType"/>
    <link:presentationArc order="1" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a4e73cf-aca7-42d8-b07c-6bd46f859c58" xlink:to="loc_dei_DocumentType_09b42bc4-586f-47b7-8d28-6fdd7e24a163" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_DocumentPeriodEndDate_22ea5524-53c6-44e3-89f2-c587ebe54dfb" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_DocumentPeriodEndDate"/>
    <link:presentationArc order="2" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a4e73cf-aca7-42d8-b07c-6bd46f859c58" xlink:to="loc_dei_DocumentPeriodEndDate_22ea5524-53c6-44e3-89f2-c587ebe54dfb" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityRegistrantName_e19fc153-586c-445a-afd0-7f024a23fa73" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityRegistrantName"/>
    <link:presentationArc order="3" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a4e73cf-aca7-42d8-b07c-6bd46f859c58" xlink:to="loc_dei_EntityRegistrantName_e19fc153-586c-445a-afd0-7f024a23fa73" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityIncorporationStateCountryCode_35f35d7a-3155-4dd4-b10b-a6dcdbb77601" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityIncorporationStateCountryCode"/>
    <link:presentationArc order="4" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a4e73cf-aca7-42d8-b07c-6bd46f859c58" xlink:to="loc_dei_EntityIncorporationStateCountryCode_35f35d7a-3155-4dd4-b10b-a6dcdbb77601" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityFileNumber_d14b5460-1767-4e77-900f-fb5a252cd142" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityFileNumber"/>
    <link:presentationArc order="5" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a4e73cf-aca7-42d8-b07c-6bd46f859c58" xlink:to="loc_dei_EntityFileNumber_d14b5460-1767-4e77-900f-fb5a252cd142" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityTaxIdentificationNumber_d5a43b6e-bb87-4a5c-a189-8a1cc7550605" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityTaxIdentificationNumber"/>
    <link:presentationArc order="6" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a4e73cf-aca7-42d8-b07c-6bd46f859c58" xlink:to="loc_dei_EntityTaxIdentificationNumber_d5a43b6e-bb87-4a5c-a189-8a1cc7550605" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressAddressLine1_2bd17c24-d9b8-4702-997c-b3c7d3c6df65" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressAddressLine1"/>
    <link:presentationArc order="7" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a4e73cf-aca7-42d8-b07c-6bd46f859c58" xlink:to="loc_dei_EntityAddressAddressLine1_2bd17c24-d9b8-4702-997c-b3c7d3c6df65" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressCityOrTown_dee24dd7-9c3b-4814-80ba-46041e2a6cd7" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressCityOrTown"/>
    <link:presentationArc order="8" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a4e73cf-aca7-42d8-b07c-6bd46f859c58" xlink:to="loc_dei_EntityAddressCityOrTown_dee24dd7-9c3b-4814-80ba-46041e2a6cd7" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressStateOrProvince_19450477-3341-4fcd-97ec-59ac0576dba9" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressStateOrProvince"/>
    <link:presentationArc order="9" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a4e73cf-aca7-42d8-b07c-6bd46f859c58" xlink:to="loc_dei_EntityAddressStateOrProvince_19450477-3341-4fcd-97ec-59ac0576dba9" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityAddressPostalZipCode_6a7f7373-dab1-4e57-989a-0d515c7d2e91" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityAddressPostalZipCode"/>
    <link:presentationArc order="10" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a4e73cf-aca7-42d8-b07c-6bd46f859c58" xlink:to="loc_dei_EntityAddressPostalZipCode_6a7f7373-dab1-4e57-989a-0d515c7d2e91" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_CityAreaCode_53085acc-6752-433a-adb6-87d232ffd400" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_CityAreaCode"/>
    <link:presentationArc order="11" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a4e73cf-aca7-42d8-b07c-6bd46f859c58" xlink:to="loc_dei_CityAreaCode_53085acc-6752-433a-adb6-87d232ffd400" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_LocalPhoneNumber_4af22022-5867-4e2f-bfa5-7ad223ec2c8c" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_LocalPhoneNumber"/>
    <link:presentationArc order="12" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a4e73cf-aca7-42d8-b07c-6bd46f859c58" xlink:to="loc_dei_LocalPhoneNumber_4af22022-5867-4e2f-bfa5-7ad223ec2c8c" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_Security12bTitle_dac0a867-e808-473d-a229-b680dc1ab602" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_Security12bTitle"/>
    <link:presentationArc order="13" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a4e73cf-aca7-42d8-b07c-6bd46f859c58" xlink:to="loc_dei_Security12bTitle_dac0a867-e808-473d-a229-b680dc1ab602" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_TradingSymbol_62387bee-0542-4e61-8de6-319aa720b7ac" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_TradingSymbol"/>
    <link:presentationArc order="14" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a4e73cf-aca7-42d8-b07c-6bd46f859c58" xlink:to="loc_dei_TradingSymbol_62387bee-0542-4e61-8de6-319aa720b7ac" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SecurityExchangeName_d99d2ffa-69b7-4c31-8a71-5e3ef1356f20" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SecurityExchangeName"/>
    <link:presentationArc order="15" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a4e73cf-aca7-42d8-b07c-6bd46f859c58" xlink:to="loc_dei_SecurityExchangeName_d99d2ffa-69b7-4c31-8a71-5e3ef1356f20" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_WrittenCommunications_b23ae533-55b5-4c29-92b6-11bca35e1a0e" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_WrittenCommunications"/>
    <link:presentationArc order="16" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a4e73cf-aca7-42d8-b07c-6bd46f859c58" xlink:to="loc_dei_WrittenCommunications_b23ae533-55b5-4c29-92b6-11bca35e1a0e" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_SolicitingMaterial_0fc22783-f44b-48ac-9cde-471f49ca26d6" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_SolicitingMaterial"/>
    <link:presentationArc order="17" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a4e73cf-aca7-42d8-b07c-6bd46f859c58" xlink:to="loc_dei_SolicitingMaterial_0fc22783-f44b-48ac-9cde-471f49ca26d6" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementTenderOffer_ee6a7f9b-238b-41d6-9f68-cae9da49f4ec" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementTenderOffer"/>
    <link:presentationArc order="18" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a4e73cf-aca7-42d8-b07c-6bd46f859c58" xlink:to="loc_dei_PreCommencementTenderOffer_ee6a7f9b-238b-41d6-9f68-cae9da49f4ec" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_PreCommencementIssuerTenderOffer_5ff5ba6e-2dae-4af7-85cc-b7bba94d6ea1" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_PreCommencementIssuerTenderOffer"/>
    <link:presentationArc order="19" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a4e73cf-aca7-42d8-b07c-6bd46f859c58" xlink:to="loc_dei_PreCommencementIssuerTenderOffer_5ff5ba6e-2dae-4af7-85cc-b7bba94d6ea1" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityEmergingGrowthCompany_4a7c558f-cdbb-4ee7-8e94-d0a840f8f466" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityEmergingGrowthCompany"/>
    <link:presentationArc order="20" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a4e73cf-aca7-42d8-b07c-6bd46f859c58" xlink:to="loc_dei_EntityEmergingGrowthCompany_4a7c558f-cdbb-4ee7-8e94-d0a840f8f466" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_AmendmentFlag_32294fdf-e7c1-4a83-892f-f03dfb24ed40" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_AmendmentFlag"/>
    <link:presentationArc order="21" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a4e73cf-aca7-42d8-b07c-6bd46f859c58" xlink:to="loc_dei_AmendmentFlag_32294fdf-e7c1-4a83-892f-f03dfb24ed40" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
    <link:loc xlink:type="locator" xlink:label="loc_dei_EntityCentralIndexKey_9d4dc5d5-fa0e-4d7d-84b2-1221630b5ea3" xlink:href="https://xbrl.sec.gov/dei/2024/dei-2024.xsd#dei_EntityCentralIndexKey"/>
    <link:presentationArc order="22" xlink:arcrole="http://www.xbrl.org/2003/arcrole/parent-child" xlink:from="loc_dei_CoverAbstract_9a4e73cf-aca7-42d8-b07c-6bd46f859c58" xlink:to="loc_dei_EntityCentralIndexKey_9d4dc5d5-fa0e-4d7d-84b2-1221630b5ea3" xlink:type="arc" preferredLabel="http://www.xbrl.org/2003/role/terseLabel"/>
  </link:presentationLink>
</link:linkbase>
</XBRL>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>supernuslogoa.jpg
<DESCRIPTION>SUPERNUS LOGO
<TEXT>
begin 644 supernuslogoa.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  ," @," @,# P,$ P,$!0@%!00$
M!0H'!P8(# H,# L*"PL-#A(0#0X1#@L+$!80$1,4%145# \7&!84&!(4%13_
MVP!# 0,$! 4$!0D%!0D4#0L-%!04%!04%!04%!04%!04%!04%!04%!04%!04
M%!04%!04%!04%!04%!04%!04%!04%!3_P  1" !P >X# 2(  A$! Q$!_\0
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MG39CPL8)Z1,>,?PGD<$U^K$<BS1JZ,'1AD,#D$>M?EV+P\\%7>'J;[KS7?\
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M789XXMZE=VT1C=@'.,C.*^$O _[-GQF\/^+_  Y?0?#+Q1'-8ZA:W$<C6#H
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M5/&U)*U*#3\SXB^#?P9\9_M>?%Z]%H"HN[LWNMZTR$P6,;L6)]W(R$3J<#H
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MY)CG$=PVQ'B8XR"4*XR2PP<>1?M+?\GV?LX?2^_]!-;W_!1JX@UK]G]_!-G
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M%M8D>YM'\3+'_96EW4!BOIY'C\SRO);!#*H8MGA0I)( S4>RG:]A\R.V_"O
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M)) !->4_M[77B+5/V8]1N)[.TTBP;4=+:>TN',UTP-[#M7*D)&0VPG!D! 8
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+"BBBD,**** /_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>8
<FILENAME>R1.htm
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<html>
<head>
<title></title>
<link rel="stylesheet" type="text/css" href="include/report.css">
<script type="text/javascript" src="Show.js">/* Do Not Remove This Comment */</script><script type="text/javascript">
							function toggleNextSibling (e) {
							if (e.nextSibling.style.display=='none') {
							e.nextSibling.style.display='block';
							} else { e.nextSibling.style.display='none'; }
							}</script>
</head>
<body>
<span style="display: none;">v3.25.1</span><table class="report" border="0" cellspacing="2" id="id2">
<tr>
<th class="tl" colspan="1" rowspan="1"><div style="width: 200px;"><strong>Cover Page<br></strong></div></th>
<th class="th"><div>May 06, 2025</div></th>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CoverAbstract', window );"><strong>Cover [Abstract]</strong></a></td>
<td class="text">&#160;<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentType', window );">Document Type</a></td>
<td class="text">8-K<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_DocumentPeriodEndDate', window );">Document Period End Date</a></td>
<td class="text">May  06,  2025<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityRegistrantName', window );">Entity Registrant Name</a></td>
<td class="text">Supernus Pharmaceuticals,&#160;Inc.<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityIncorporationStateCountryCode', window );">Entity Incorporation, State or Country Code</a></td>
<td class="text">DE<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityFileNumber', window );">Entity Filer Name</a></td>
<td class="text">001-35518<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityTaxIdentificationNumber', window );">Entity Tax Identification Number</a></td>
<td class="text">20-2590184<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressAddressLine1', window );">Entity Address, Address Line One</a></td>
<td class="text">9715 Key West Ave<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressCityOrTown', window );">Entity Address, City or Town</a></td>
<td class="text">Rockville<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressStateOrProvince', window );">Entity Address, State or Province</a></td>
<td class="text">MD<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityAddressPostalZipCode', window );">Entity Address, Postal Zip Code</a></td>
<td class="text">20850<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_CityAreaCode', window );">City Area Code</a></td>
<td class="text">301<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_LocalPhoneNumber', window );">Local Phone Number</a></td>
<td class="text">838-2500<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_Security12bTitle', window );">Title of 12(b) Security</a></td>
<td class="text">Common Stock, $0.001 par value per share<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_TradingSymbol', window );">Trading Symbol</a></td>
<td class="text">SUPN<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SecurityExchangeName', window );">Security Exchange Name</a></td>
<td class="text">NASDAQ<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_WrittenCommunications', window );">Written Communications</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_SolicitingMaterial', window );">Soliciting Material</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementTenderOffer', window );">Pre-commencement Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_PreCommencementIssuerTenderOffer', window );">Pre-commencement Issuer Tender Offer</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityEmergingGrowthCompany', window );">Entity Emerging Growth Company</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="ro">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_AmendmentFlag', window );">Amendment Flag</a></td>
<td class="text">false<span></span>
</td>
</tr>
<tr class="re">
<td class="pl" style="border-bottom: 0px;" valign="top"><a class="a" href="javascript:void(0);" onclick="Show.showAR( this, 'defref_dei_EntityCentralIndexKey', window );">Entity Central Index Key</a></td>
<td class="text">0001356576<span></span>
</td>
</tr>
</table>
<div style="display: none;">
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_AmendmentFlag">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_AmendmentFlag</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CityAreaCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Area code of city</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CityAreaCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_CoverAbstract">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Cover page.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_CoverAbstract</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:stringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentPeriodEndDate">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentPeriodEndDate</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:dateItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_DocumentType">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_DocumentType</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:submissionTypeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressAddressLine1">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Address Line 1 such as Attn, Building Name, Street Name</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressAddressLine1</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressCityOrTown">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the City or Town</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressCityOrTown</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressPostalZipCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Code for the postal or zip code</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressPostalZipCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityAddressStateOrProvince">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the state or province.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityAddressStateOrProvince</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:stateOrProvinceItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityCentralIndexKey">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityCentralIndexKey</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:centralIndexKeyItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityEmergingGrowthCompany">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Indicate if registrant meets the emerging growth company criteria.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityEmergingGrowthCompany</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityFileNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityFileNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:fileNumberItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityIncorporationStateCountryCode">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Two-character EDGAR code representing the state or country of incorporation.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityIncorporationStateCountryCode</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarStateCountryItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityRegistrantName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityRegistrantName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_EntityTaxIdentificationNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b-2<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_EntityTaxIdentificationNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:employerIdItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_LocalPhoneNumber">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Local phone number for entity.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_LocalPhoneNumber</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:normalizedStringItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementIssuerTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 13e<br> -Subsection 4c<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementIssuerTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_PreCommencementTenderOffer">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14d<br> -Subsection 2b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_PreCommencementTenderOffer</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_Security12bTitle">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Title of a 12(b) registered security.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection b<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_Security12bTitle</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:securityTitleItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SecurityExchangeName">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Name of the Exchange on which a security is registered.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 12<br> -Subsection d1-1<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SecurityExchangeName</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:edgarExchangeCodeItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_SolicitingMaterial">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Exchange Act<br> -Number 240<br> -Section 14a<br> -Subsection 12<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_SolicitingMaterial</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_TradingSymbol">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Trading symbol of an instrument as listed on an exchange.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>No definition available.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_TradingSymbol</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>dei:tradingSymbolItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
<table border="0" cellpadding="0" cellspacing="0" class="authRefData" style="display: none;" id="defref_dei_WrittenCommunications">
<tr><td class="hide"><a style="color: white;" href="javascript:void(0);" onclick="Show.hideAR();">X</a></td></tr>
<tr><td><div class="body" style="padding: 2px;">
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">- Definition</a><div><p>Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.</p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ References</a><div style="display: none;"><p>Reference 1: http://www.xbrl.org/2003/role/presentationRef<br> -Publisher SEC<br> -Name Securities Act<br> -Number 230<br> -Section 425<br></p></div>
<a href="javascript:void(0);" onclick="Show.toggleNext( this );">+ Details</a><div style="display: none;"><table border="0" cellpadding="0" cellspacing="0">
<tr>
<td><strong> Name:</strong></td>
<td style="white-space:nowrap;">dei_WrittenCommunications</td>
</tr>
<tr>
<td style="padding-right: 4px;white-space:nowrap;"><strong> Namespace Prefix:</strong></td>
<td>dei_</td>
</tr>
<tr>
<td><strong> Data Type:</strong></td>
<td>xbrli:booleanItemType</td>
</tr>
<tr>
<td><strong> Balance Type:</strong></td>
<td>na</td>
</tr>
<tr>
<td><strong> Period Type:</strong></td>
<td>duration</td>
</tr>
</table></div>
</div></td></tr>
</table>
</div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EXCEL
<SEQUENCE>9
<FILENAME>Financial_Report.xlsx
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 Financial_Report.xlsx
M4$L#!!0    ( ,B!IEI&QTU(E0   ,T    0    9&]C4')O<',O87!P+GAM
M;$W/30O", P&X+]2=K>9BAZD#D0]BIZ\SRYUA;8I;83Z[^T$/VYY><@;HBZ)
M(B:VF$7Q+N1M,S+'#4#6(_H^R\JABJ'D>ZXQW8&,L1H/I!\> \.B;=> A3$,
M.,SBM[#IU"Y&9W7/ED)WLCI1)L/B6#0ZL2<?J]P<"A#G>B4^BQ-+.9<K!?^+
M4\L54Y[FRF_\9 6_![H74$L#!!0    ( ,B!IEK>%K=%[P   "L"   1
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M@2";_-;;I/;=X Q\U*M:I60K$3]+!WP?D@9CC%OT-%^/%&*MIK&MQMHQ#'F
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M<6A4"H[<8R6,<6*T_C6"R0_L?@!02P,$%     @ R(&F6AE%%?4W 0  )P(
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M1NO<2KGW\$JV''..?[3\ 5!+ P04    " #(@:9:)!Z;HJT   #X 0  &@
M 'AL+U]R96QS+W=O<FMB;V]K+GAM;"YR96QSM9$]#H,P#(6O$N4 -5"I0P5,
M75@K+A %\R,2$L6N"K<OA0&0.G1ALIXM?^_)3I]H%'=NH+;S)$9K!LIDR^SO
M *1;M(HNSN,P3VH7K.)9A@:\TKUJ$)(HND'8,V2>[IFBG#S^0W1UW6E\./VR
M./ /,+Q=Z*E%9"E*%1KD3,)HMC;!4N++3):BJ#(9BBJ6<%H@XLD@;6E6?;!/
M3K3G>1<W]T6NS>,)KM\,<'AT_@%02P,$%     @ R(&F6F60>9(9 0  SP,
M !,   !;0V]N=&5N=%]4>7!E<UTN>&ULK9--3L,P$(6O$F5;)2XL6*"F&V +
M77 !8T\:J_Z39UK2VS-.VDJ@$A6%3:QXWKS/GI>LWH\1L.B=]=B4'5%\% )5
M!TYB'2)XKK0A.4G\FK8B2K636Q#WR^6#4,$3>*HH>Y3KU3.T<F^I>.EY&TWP
M39G 8ED\C<+,:DH9HS5*$M?%P>L?E.I$J+EST&!G(BY84(JKA%SY'7#J>SM
M2D9#L9&)7J5CE>BM0#I:P'K:XLH90]L:!3JHO>.6&F,"J;$#(&?KT70Q32:>
M,(S/N]G\P68*R,I-"A$YL01_QYTCR=U59"-(9*:O>"&R]>S[04Y;@[Z1S>/]
M#&DWY(%B6.;/^'O&%_\;SO$1PNZ_/[&\UDX:?^:+X3]>?P%02P$"% ,4
M" #(@:9:1L=-2)4   #-    $               @ $     9&]C4')O<',O
M87!P+GAM;%!+ 0(4 Q0    ( ,B!IEK>%K=%[P   "L"   1
M  "  <,   !D;V-0<F]P<R]C;W)E+GAM;%!+ 0(4 Q0    ( ,B!IEJ97)PC
M$ 8  )PG   3              "  >$!  !X;"]T:&5M92]T:&5M93$N>&UL
M4$L! A0#%     @ R(&F6HOPJ:-0!   C1   !@              ("!(@@
M 'AL+W=O<FMS:&5E=',O<VAE970Q+GAM;%!+ 0(4 Q0    ( ,B!IEJ?H!OP
ML0(  .(,   -              "  :@,  !X;"]S='EL97,N>&UL4$L! A0#
M%     @ R(&F6I>*NQS     $P(   L              ( !A \  %]R96QS
M+RYR96QS4$L! A0#%     @ R(&F6AE%%?4W 0  )P(   \
M ( !;1   'AL+W=O<FMB;V]K+GAM;%!+ 0(4 Q0    ( ,B!IEHD'INBK0
M /@!   :              "  =$1  !X;"]?<F5L<R]W;W)K8F]O:RYX;6PN
M<F5L<U!+ 0(4 Q0    ( ,B!IEIED'F2&0$  ,\#   3              "
M ;82  !;0V]N=&5N=%]4>7!E<UTN>&UL4$L%!@     )  D /@(    4
!  $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>10
<FILENAME>Show.js
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
// Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission.  Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105.
var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0);
e.removeAttribute('id');a.parentNode.appendChild(e)}}
if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'}
e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>11
<FILENAME>report.css
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
/* Updated 2009-11-04 */
/* v2.2.0.24 */

/* DefRef Styles */
.report table.authRefData{
	background-color: #def;
	border: 2px solid #2F4497;
	font-size: 1em;
	position: absolute;
}

.report table.authRefData a {
	display: block;
	font-weight: bold;
}

.report table.authRefData p {
	margin-top: 0px;
}

.report table.authRefData .hide {
	background-color: #2F4497;
	padding: 1px 3px 0px 0px;
	text-align: right;
}

.report table.authRefData .hide a:hover {
	background-color: #2F4497;
}

.report table.authRefData .body {
	height: 150px;
	overflow: auto;
	width: 400px;
}

.report table.authRefData table{
	font-size: 1em;
}

/* Report Styles */
.pl a, .pl a:visited {
	color: black;
	text-decoration: none;
}

/* table */
.report {
	background-color: white;
	border: 2px solid #acf;
	clear: both;
	color: black;
	font: normal 8pt Helvetica, Arial, san-serif;
	margin-bottom: 2em;
}

.report hr {
	border: 1px solid #acf;
}

/* Top labels */
.report th {
	background-color: #acf;
	color: black;
	font-weight: bold;
	text-align: center;
}

.report th.void	{
	background-color: transparent;
	color: #000000;
	font: bold 10pt Helvetica, Arial, san-serif;
	text-align: left;
}

.report .pl {
	text-align: left;
	vertical-align: top;
	white-space: normal;
	width: 200px;
	white-space: normal; /* word-wrap: break-word; */
}

.report td.pl a.a {
	cursor: pointer;
	display: block;
	width: 200px;
	overflow: hidden;
}

.report td.pl div.a {
	width: 200px;
}

.report td.pl a:hover {
	background-color: #ffc;
}

/* Header rows... */
.report tr.rh {
	background-color: #acf;
	color: black;
	font-weight: bold;
}

/* Calendars... */
.report .rc {
	background-color: #f0f0f0;
}

/* Even rows... */
.report .re, .report .reu {
	background-color: #def;
}

.report .reu td {
	border-bottom: 1px solid black;
}

/* Odd rows... */
.report .ro, .report .rou {
	background-color: white;
}

.report .rou td {
	border-bottom: 1px solid black;
}

.report .rou table td, .report .reu table td {
	border-bottom: 0px solid black;
}

/* styles for footnote marker */
.report .fn {
	white-space: nowrap;
}

/* styles for numeric types */
.report .num, .report .nump {
	text-align: right;
	white-space: nowrap;
}

.report .nump {
	padding-left: 2em;
}

.report .nump {
	padding: 0px 0.4em 0px 2em;
}

/* styles for text types */
.report .text {
	text-align: left;
	white-space: normal;
}

.report .text .big {
	margin-bottom: 1em;
	width: 17em;
}

.report .text .more {
	display: none;
}

.report .text .note {
	font-style: italic;
	font-weight: bold;
}

.report .text .small {
	width: 10em;
}

.report sup {
	font-style: italic;
}

.report .outerFootnotes {
	font-size: 1em;
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>13
<FILENAME>FilingSummary.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version='1.0' encoding='utf-8'?>
<FilingSummary>
  <Version>3.25.1</Version>
  <ProcessingTime/>
  <ReportFormat>html</ReportFormat>
  <ContextCount>1</ContextCount>
  <ElementCount>22</ElementCount>
  <EntityCount>1</EntityCount>
  <FootnotesReported>false</FootnotesReported>
  <SegmentCount>0</SegmentCount>
  <ScenarioCount>0</ScenarioCount>
  <TuplesReported>false</TuplesReported>
  <UnitCount>0</UnitCount>
  <MyReports>
    <Report instance="supn-20250506.htm">
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <HtmlFileName>R1.htm</HtmlFileName>
      <LongName>0000001 - Document - Cover Page</LongName>
      <ReportType>Sheet</ReportType>
      <Role>http://www.supernus.com/role/CoverPage</Role>
      <ShortName>Cover Page</ShortName>
      <MenuCategory>Cover</MenuCategory>
      <Position>1</Position>
    </Report>
    <Report>
      <IsDefault>false</IsDefault>
      <HasEmbeddedReports>false</HasEmbeddedReports>
      <LongName>All Reports</LongName>
      <ReportType>Book</ReportType>
      <ShortName>All Reports</ShortName>
    </Report>
  </MyReports>
  <InputFiles>
    <File doctype="8-K" isOnlyDei="true" original="supn-20250506.htm">supn-20250506.htm</File>
    <File>supn-20250506.xsd</File>
    <File>supn-20250506_lab.xml</File>
    <File>supn-20250506_pre.xml</File>
  </InputFiles>
  <SupplementalFiles/>
  <BaseTaxonomies>
    <BaseTaxonomy items="22">http://xbrl.sec.gov/dei/2024</BaseTaxonomy>
  </BaseTaxonomies>
  <HasPresentationLinkbase>true</HasPresentationLinkbase>
  <HasCalculationLinkbase>false</HasCalculationLinkbase>
</FilingSummary>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>JSON
<SEQUENCE>15
<FILENAME>MetaLinks.json
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
{
 "version": "2.2",
 "instance": {
  "supn-20250506.htm": {
   "nsprefix": "supn",
   "nsuri": "http://www.supernus.com/20250506",
   "dts": {
    "inline": {
     "local": [
      "supn-20250506.htm"
     ]
    },
    "schema": {
     "local": [
      "supn-20250506.xsd"
     ],
     "remote": [
      "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xl-2003-12-31.xsd",
      "http://www.xbrl.org/2003/xlink-2003-12-31.xsd",
      "http://www.xbrl.org/2005/xbrldt-2005.xsd",
      "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd",
      "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd",
      "https://www.xbrl.org/dtr/type/2022-03-31/types.xsd",
      "https://xbrl.sec.gov/dei/2024/dei-2024.xsd"
     ]
    },
    "labelLink": {
     "local": [
      "supn-20250506_lab.xml"
     ]
    },
    "presentationLink": {
     "local": [
      "supn-20250506_pre.xml"
     ]
    }
   },
   "keyStandard": 22,
   "keyCustom": 0,
   "axisStandard": 0,
   "axisCustom": 0,
   "memberStandard": 0,
   "memberCustom": 0,
   "hidden": {
    "total": 2,
    "http://xbrl.sec.gov/dei/2024": 2
   },
   "contextCount": 1,
   "entityCount": 1,
   "segmentCount": 0,
   "elementCount": 23,
   "unitCount": 0,
   "baseTaxonomies": {
    "http://xbrl.sec.gov/dei/2024": 22
   },
   "report": {
    "R1": {
     "role": "http://www.supernus.com/role/CoverPage",
     "longName": "0000001 - Document - Cover Page",
     "shortName": "Cover Page",
     "isDefault": "true",
     "groupType": "document",
     "subGroupType": "",
     "menuCat": "Cover",
     "order": "1",
     "firstAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "supn-20250506.htm",
      "first": true,
      "unique": true
     },
     "uniqueAnchor": {
      "contextRef": "c-1",
      "name": "dei:DocumentType",
      "unitRef": null,
      "xsiNil": "false",
      "lang": "en-US",
      "decimals": null,
      "ancestors": [
       "span",
       "div",
       "body",
       "html"
      ],
      "reportCount": 1,
      "baseRef": "supn-20250506.htm",
      "first": true,
      "unique": true
     }
    }
   },
   "tag": {
    "dei_AmendmentFlag": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "AmendmentFlag",
     "presentation": [
      "http://www.supernus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Amendment Flag",
        "label": "Amendment Flag",
        "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission."
       }
      }
     },
     "auth_ref": []
    },
    "dei_CityAreaCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CityAreaCode",
     "presentation": [
      "http://www.supernus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "City Area Code",
        "label": "City Area Code",
        "documentation": "Area code of city"
       }
      }
     },
     "auth_ref": []
    },
    "dei_CoverAbstract": {
     "xbrltype": "stringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "CoverAbstract",
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Cover [Abstract]",
        "label": "Cover [Abstract]",
        "documentation": "Cover page."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentPeriodEndDate": {
     "xbrltype": "dateItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentPeriodEndDate",
     "presentation": [
      "http://www.supernus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Period End Date",
        "label": "Document Period End Date",
        "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD."
       }
      }
     },
     "auth_ref": []
    },
    "dei_DocumentType": {
     "xbrltype": "submissionTypeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "DocumentType",
     "presentation": [
      "http://www.supernus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Document Type",
        "label": "Document Type",
        "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressAddressLine1": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressAddressLine1",
     "presentation": [
      "http://www.supernus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Address Line One",
        "label": "Entity Address, Address Line One",
        "documentation": "Address Line 1 such as Attn, Building Name, Street Name"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressCityOrTown": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressCityOrTown",
     "presentation": [
      "http://www.supernus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, City or Town",
        "label": "Entity Address, City or Town",
        "documentation": "Name of the City or Town"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressPostalZipCode": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressPostalZipCode",
     "presentation": [
      "http://www.supernus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, Postal Zip Code",
        "label": "Entity Address, Postal Zip Code",
        "documentation": "Code for the postal or zip code"
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityAddressStateOrProvince": {
     "xbrltype": "stateOrProvinceItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityAddressStateOrProvince",
     "presentation": [
      "http://www.supernus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Address, State or Province",
        "label": "Entity Address, State or Province",
        "documentation": "Name of the state or province."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityCentralIndexKey": {
     "xbrltype": "centralIndexKeyItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityCentralIndexKey",
     "presentation": [
      "http://www.supernus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Central Index Key",
        "label": "Entity Central Index Key",
        "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityEmergingGrowthCompany": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityEmergingGrowthCompany",
     "presentation": [
      "http://www.supernus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Emerging Growth Company",
        "label": "Entity Emerging Growth Company",
        "documentation": "Indicate if registrant meets the emerging growth company criteria."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityFileNumber": {
     "xbrltype": "fileNumberItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityFileNumber",
     "presentation": [
      "http://www.supernus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Filer Name",
        "label": "Entity File Number",
        "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityIncorporationStateCountryCode": {
     "xbrltype": "edgarStateCountryItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityIncorporationStateCountryCode",
     "presentation": [
      "http://www.supernus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Incorporation, State or Country Code",
        "label": "Entity Incorporation, State or Country Code",
        "documentation": "Two-character EDGAR code representing the state or country of incorporation."
       }
      }
     },
     "auth_ref": []
    },
    "dei_EntityRegistrantName": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityRegistrantName",
     "presentation": [
      "http://www.supernus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Registrant Name",
        "label": "Entity Registrant Name",
        "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_EntityTaxIdentificationNumber": {
     "xbrltype": "employerIdItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "EntityTaxIdentificationNumber",
     "presentation": [
      "http://www.supernus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Entity Tax Identification Number",
        "label": "Entity Tax Identification Number",
        "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS."
       }
      }
     },
     "auth_ref": [
      "r1"
     ]
    },
    "dei_LocalPhoneNumber": {
     "xbrltype": "normalizedStringItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "LocalPhoneNumber",
     "presentation": [
      "http://www.supernus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Local Phone Number",
        "label": "Local Phone Number",
        "documentation": "Local phone number for entity."
       }
      }
     },
     "auth_ref": []
    },
    "dei_PreCommencementIssuerTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementIssuerTenderOffer",
     "presentation": [
      "http://www.supernus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Issuer Tender Offer",
        "label": "Pre-commencement Issuer Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r3"
     ]
    },
    "dei_PreCommencementTenderOffer": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "PreCommencementTenderOffer",
     "presentation": [
      "http://www.supernus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Pre-commencement Tender Offer",
        "label": "Pre-commencement Tender Offer",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r5"
     ]
    },
    "dei_Security12bTitle": {
     "xbrltype": "securityTitleItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "Security12bTitle",
     "presentation": [
      "http://www.supernus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Title of 12(b) Security",
        "label": "Title of 12(b) Security",
        "documentation": "Title of a 12(b) registered security."
       }
      }
     },
     "auth_ref": [
      "r0"
     ]
    },
    "dei_SecurityExchangeName": {
     "xbrltype": "edgarExchangeCodeItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SecurityExchangeName",
     "presentation": [
      "http://www.supernus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Security Exchange Name",
        "label": "Security Exchange Name",
        "documentation": "Name of the Exchange on which a security is registered."
       }
      }
     },
     "auth_ref": [
      "r2"
     ]
    },
    "dei_SolicitingMaterial": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "SolicitingMaterial",
     "presentation": [
      "http://www.supernus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Soliciting Material",
        "label": "Soliciting Material",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act."
       }
      }
     },
     "auth_ref": [
      "r4"
     ]
    },
    "dei_TradingSymbol": {
     "xbrltype": "tradingSymbolItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "TradingSymbol",
     "presentation": [
      "http://www.supernus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Trading Symbol",
        "label": "Trading Symbol",
        "documentation": "Trading symbol of an instrument as listed on an exchange."
       }
      }
     },
     "auth_ref": []
    },
    "dei_WrittenCommunications": {
     "xbrltype": "booleanItemType",
     "nsuri": "http://xbrl.sec.gov/dei/2024",
     "localname": "WrittenCommunications",
     "presentation": [
      "http://www.supernus.com/role/CoverPage"
     ],
     "lang": {
      "en-us": {
       "role": {
        "terseLabel": "Written Communications",
        "label": "Written Communications",
        "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act."
       }
      }
     },
     "auth_ref": [
      "r6"
     ]
    }
   }
  }
 },
 "std_ref": {
  "r0": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b"
  },
  "r1": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "b-2"
  },
  "r2": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "12",
   "Subsection": "d1-1"
  },
  "r3": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "13e",
   "Subsection": "4c"
  },
  "r4": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14a",
   "Subsection": "12"
  },
  "r5": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Exchange Act",
   "Number": "240",
   "Section": "14d",
   "Subsection": "2b"
  },
  "r6": {
   "role": "http://www.xbrl.org/2003/role/presentationRef",
   "Publisher": "SEC",
   "Name": "Securities Act",
   "Number": "230",
   "Section": "425"
  }
 }
}
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>ZIP
<SEQUENCE>16
<FILENAME>0001356576-25-000031-xbrl.zip
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
begin 644 0001356576-25-000031-xbrl.zip
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MV?CU_?LKE>"L);D_<\<!A1>VRV6QVCEDX4S0?PC8Z=,!=U"RH\LB1FD=MH<
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M^]\V6JJN71V$*VA<IRB9G43ZXWPBR"U;JK8X!^Q+L-L,S(-Z;]98=P2V%&Y
M#!J,Y=^$_3?B3]3!7HA2XB2MT/"SX\&(V%DM%CJR%0:#6WC(62 Q=K$-W%NS
M8ZB=%'46V)79SEZB0BR_9Q:;#)B_A#E$=*A)&S6OE<)B_B!]9:\BV<HXYK_8
M_@C>B]UD'6RC-,3.;''_(>2_K7064SI[211O[:*\A;5>8B,WO;2-W,[=5RIR
M'/(?8,8"JS+&Q\\1M[%S<C$:D&X%_D])VW5<RRQ9RV(O:I_Q4!!L('J;SV^=
MMVH:Q2M&#H%T"T(G'),!<[SGW5KW;-N?TK3U:0/RM_9K6[-M6!.88+^?:]CC
MM>THJKMG0Z.$6!*F% B8U)!2ZR<V\$$.8$=A*5,7#\D_4=9PNCM%B?,T7ED!
MVNC'63^[M+'=DHK2::?BOTG>=N?? +); E1E#$:UKQJ=EY*@=XLTEZ0QS(;H
M00>,&(!YQV@=1K#[167/NG:0P /XT2:?O__.Z-V\%^C]^+/X<IOZDO9JOU!*
M;_Y;TV@C+IB= W'A0.9]CK7?KW%3H3<B3Z^7BN1XOVUH[2N$OW9>5G VV9W/
M9UE"F;<I :/"K$QK"5:FK1-K+P7ISFSX;N\>O-&YLC%\N-[@>_&Q4]O*7U8Z
M#8MP$N5NL*8-,IC0-!2WHT&ROJOQ\YA;8V)C]^-0^-U U7WF8#G_R\4V7N0Q
M%%:W=)BA6XP"WYZ*-N26!20@.,#4!Z693T42EJ!_&0S;TJ$9>XM'C@WV>1H$
M8R+P@!0D)A9ZBI@3F$Z4!-$ MCV,0B:<R:(9-.&@4,;=PWUOHN"O021"&#XZ
M^M)7P09(;R(.#Y/VI9] K!*GIY(4F^@6[H;.1P+['WH^4K!0A,! ^)U9^ !P
M$@"-?#X0D\35"V>C<(\WD=788H=!8Y+3CK4GA=@,YFC%S:EQ7#KQ@$_\067_
M:@X0=D<<70\T0-\&GTPI]X4'TH+!1TPZYV7P4;1:'\)U\D2=2/CE-X4<I>\6
M)SND%JPKQACTYD=N%$344<0R?'3>^K@;<&ODPF1M;@D&(4>0F7H"X3R!D@'Z
MA1/E4,F4A0936.>0(S!"-@D2Y)3 08_/4J=N\9) 7EQILIWM\KW0P'L+&!7R
M#+OH!%Y*%^&FK,-Y9N&2A2=Q?"434?ZLQ"2%V#"?48R,XAFX OAC1=)A3(.5
M1M-R> >7NG("Q$YS4<E?&3!K7'BRO\)K1M,Q07U+UASP)QZF;G)!\-PBL$,^
M%6Y^V+<Y%X@9!H(81ED[RR""78A_%3B)J!<3,5 T,%- ! O&%CYW?,*+TKKA
MU'L>A;!M*ODW0U<>AL EBN*U*!#(O8W+I!V^X=YAY"!_ "Z%A+/$!I%?4)>.
MQ#6DN"?TXOL"=ZDS0YI.D3C(]@B?.RDQFJ-U;X)T"?@ 3")R0K$?F2"#(/$
M&$;XTEN5[&MA3T#G@$_ #NPDL,^0RB6.9_</])-GX&]X!\X1WBT6BXQ/=*R'
M_02(NX!C6V(1Y1>7(M0$_SM\PL-D]X/ 0V8+Q"=D0$Y<BK?29["1+ Y1T0%P
M*B":"9VA*!-O8;:0?L'B2V.ODG Z;WV-0&\<#^D+Q@3,X#XZH)(W.H(^ Q@;
M:!U^!Y)R,/"4#!"AG!G,8H8KGG(Y"^#-_1M< $PL&1[6XB#] DG'_!CV &;J
M35C,UV,!184WS %R%3Q?2HGA$)]%I)NC=OH6GR6;,O5"7 .LT>;PB,\ !P.4
M<("Q"1]$$IPPD!XV8,9HS6SEHS):%V95BRP1;UBY$F^^T%18]HK@*P C/@)L
MB-^6!=I@-I=',;%O!EV2JC,!Z9<%UOJ[47C%U"X0%'8%=A)8@0AZ A5S((%5
M@2@5JV6.(X(_:T(A*(-0U V8U-($,[11DP'# YB#G)O@1O.%"4WFQ2!\[-1;
MGY!WVC!)OZ^:6GN?*(G64_NMS9?WC9+4P^XV[$O.DRW]QPOJ/UL?&OH A/8)
MN&$N=VF>1>\0/#O!K0M^@U-[?O1C>'[.H:.01\9D!AY(4Z&*2GDNDH-:-]L=
M'>(F[4:8<%E)2 =>%$J3:;/ 4LGMLKD%XI]14-MS2CD;-!,K7-1--CS&4Q4(
MA(W4WQEJML-UAMU!PJ=$F*>?%_,^_O.WC[?$IB%%.P4=/<*E\/<(()HW&:\J
MH##.#(HDZ+S6E/[U/_=__>7^[EQ>]?VW]?OOM*YYQ@3'-^\4\C^W[V]_OJ_W
M;@^L%%ZE8.(Y[!OY\+G>PMVW\&+XIWE%SKG/JV<19KW.J6LU5D&(+V['9&10
M>A)79\:MJF2=J4H\BAR:V7.GIO#FNG@CJ$$1:#MP90I;-+L8L+<+*S:%]S4/
M5EP,K#KGA=5GZ6P,XFA4!(24!AE\6-'Z3+HUMV3C'(-L?.,1 Y-8%I"S?.DL
M5:5;P]IWGAM[2,D=.F7?LY!R9W,!:0$6LA[:CQB(=:. /'-8QAB-18J 3U9G
MX>H0OL]L8-$ HW V!4+]E<Y()RDX 3O1% YSHT6FZD0E'^!.&);@5-$0M7E@
M14$0>V[C6,M.]4.%V;!;X%%/+-T.L6T#1N@3P%_8U7% ;!L),T-GVBO.\<,3
M%OP0D?M''F3X5'K*S\I8$L=)'-=:=HXG?G9@0$[LUX==!@YZWLU\?GY6@YA*
M5,N;?/^=V;U)(X"%UED+24 /6+AE\2D&JT7(* GR-WV0$<@W"%:2A,@Z!C*&
MA]@B&-$Y\0!#96>%-KE'ABPW*:Y$QPP%3 5B(;,561*7[&S"F-)@$@4N#-H&
ML"<W$K)7Q%0I1IP#SP7,^$.DO<PYOV<+WHUY1))U"QBHY$'F,]DR0XEHF&#O
M1J&(XL<I/<)-&F*V ()Q,YY>8@V=4;X:NL+PCI\\Q_&>DQ"O$,2(DZ"! %U@
MC'*-//;<K+3Y<RUG]N \&,O>K/$L[G JSY--Q9A'IT5 ;<1\N[4 S&?:%<H"
MN!61FU1]?AA3?T(M%@F;+E#0XBWTJEXP!Y;6([/D!MR;+OP>9VC, *Z62.H
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M Y>G* L4]+MA KSGSV(%':TBY)%RC2NV#MNZ37/5-=<\X;$0V3FBSMHX=KJ
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MH_W0B46#CLA+/GRSG,B& >E+)UJKBVV2,C")69;(A6HM"D.+X4D*,43>_3A
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M<.WYP'2 /0/R+>28"2(7_4VK?U=#L[D*^17T!S ZVMPD3#<RY;(.&411,*#
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MB &1<1Q3A G$VH^P[\''@<OIE=%'/O>ND5O3T!>H,'-!+#FI:*7UG!3M.A@
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MN7UT^F+S3+[Z8YVG+_X'4$L#!!0    ( ,B!IEI!Q8PRK@8  .HP   5
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M_\#L( ;8]!EXOI8O#,.;JBW:V_>X+#HEJO8WL\8%ICJX5/(.9IH<A31@@D]
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MD\N<A>!%DHS"X7-KPP"8<#OSV=*]<,J['S[*RU5=[;9/P@1&:6)=SZ7;/K$
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MT?!J_DC$"SIP<G!_HOOH7HT_.?@_4$L! A0#%     @ R(&F6E1JZ]#P+P
M?I<" !@              ( !     &5X.3DQ96%R;FEN9W-R96QE87-E+FAT
M;5!+ 0(4 Q0    ( ,B!IEI=*(OY%Q,  #R    1              "  28P
M  !S=7!N+3(P,C4P-3 V+FAT;5!+ 0(4 Q0    ( ,B!IEIPWS #9@(   8'
M   1              "  6Q#  !S=7!N+3(P,C4P-3 V+GAS9%!+ 0(4 Q0
M   ( ,B!IEH?K11&, H  'Q5   5              "  0%&  !S=7!N+3(P
M,C4P-3 V7VQA8BYX;6Q02P$"% ,4    " #(@:9:0<6,,JX&  #J,   %0
M            @ %D4   <W5P;BTR,#(U,#4P-E]P<F4N>&UL4$L%!@     %
-  4 2@$  $57      $!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>XML
<SEQUENCE>17
<FILENAME>supn-20250506_htm.xml
<DESCRIPTION>IDEA: XBRL DOCUMENT
<TEXT>
<XML>
<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xml:lang="en-US"
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:dei="http://xbrl.sec.gov/dei/2024"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:xlink="http://www.w3.org/1999/xlink">
    <link:schemaRef xlink:href="supn-20250506.xsd" xlink:type="simple"/>
    <context id="c-1">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001356576</identifier>
        </entity>
        <period>
            <startDate>2025-05-06</startDate>
            <endDate>2025-05-06</endDate>
        </period>
    </context>
    <dei:AmendmentFlag contextRef="c-1" id="f-21">false</dei:AmendmentFlag>
    <dei:EntityCentralIndexKey contextRef="c-1" id="f-22">0001356576</dei:EntityCentralIndexKey>
    <dei:DocumentType contextRef="c-1" id="f-1">8-K</dei:DocumentType>
    <dei:DocumentPeriodEndDate contextRef="c-1" id="f-2">2025-05-06</dei:DocumentPeriodEndDate>
    <dei:EntityRegistrantName contextRef="c-1" id="f-3">Supernus Pharmaceuticals,&#160;Inc.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="c-1" id="f-4">DE</dei:EntityIncorporationStateCountryCode>
    <dei:EntityFileNumber contextRef="c-1" id="f-5">001-35518</dei:EntityFileNumber>
    <dei:EntityTaxIdentificationNumber contextRef="c-1" id="f-6">20-2590184</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="c-1" id="f-7">9715 Key West Ave</dei:EntityAddressAddressLine1>
    <dei:EntityAddressCityOrTown contextRef="c-1" id="f-8">Rockville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="c-1" id="f-9">MD</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="c-1" id="f-10">20850</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="c-1" id="f-11">301</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="c-1" id="f-12">838-2500</dei:LocalPhoneNumber>
    <dei:Security12bTitle contextRef="c-1" id="f-13">Common Stock, $0.001 par value per share</dei:Security12bTitle>
    <dei:TradingSymbol contextRef="c-1" id="f-14">SUPN</dei:TradingSymbol>
    <dei:SecurityExchangeName contextRef="c-1" id="f-15">NASDAQ</dei:SecurityExchangeName>
    <dei:WrittenCommunications contextRef="c-1" id="f-16">false</dei:WrittenCommunications>
    <dei:SolicitingMaterial contextRef="c-1" id="f-17">false</dei:SolicitingMaterial>
    <dei:PreCommencementTenderOffer contextRef="c-1" id="f-18">false</dei:PreCommencementTenderOffer>
    <dei:PreCommencementIssuerTenderOffer contextRef="c-1" id="f-19">false</dei:PreCommencementIssuerTenderOffer>
    <dei:EntityEmergingGrowthCompany contextRef="c-1" id="f-20">false</dei:EntityEmergingGrowthCompany>
</xbrl>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
